KARDIO-ONKOLOGIYA: SARATON KASALLIGINI DAVOLASHDA YUZAGA KELADIGAN YURAK-QON TOMIR TOKSIKLIGINI OLDINI OLISH VA BOSHQARISH
Keywords:
kardio-onkologiya, yurak-qon tomir toksikligi, CTR-CVT, antrasiklinlar, HER2 terapiyasi, immunoterapiya, ekokardiyografiya, global bo‘ylama strain, troponin, kardioproteksiya.Abstract
Ushbu maqolada saratonga qarshi davolash bilan bog‘liq yurak-qon tomir toksikligi (cancer therapy-related cardiovascular toxicity, CTR-CVT)ning klinik shakllari, rivojlanish mexanizmlari, xavf omillari, diagnostikasi va boshqaruvi zamonaviy xalqaro tavsiyalar asosida tahlil qilinadi. Kardio-onkologiyaning asosiy vazifasi saratonga qarshi davolashning onkologik samaradorligini saqlab qolgan holda yurak-qon tomir asoratlarini erta aniqlash va ularning og‘irligini kamaytirishdan iborat. Ishda antrasiklinlar, HER2-ga yo‘naltirilgan preparatlar, VEGF signal yo‘li ingibitorlari, fluoropirimidinlar, immun nazorat nuqtasi ingibitorlari hamda ko‘krak qafasi radioterapiyasining o‘ziga xos toksik profili ko‘rib chiqildi. Tahlil natijalari davolashdan oldingi xavfni stratifikatsiya qilish, arterial bosim va metabolik xavf omillarini nazorat etish, EKG, ekokardiyografiya, global bo‘ylama strain (GLS), troponin va natriuretik peptidlarni klinik vaziyatga mos qo‘llash muhimligini ko‘rsatdi. Yuqori xavfli bemorlarda kardiolog, onkolog va radioterapevtning hamkorlikdagi qarori davolash uzluksizligini saqlash va qaytariladigan yurak-qon tomir zararlanishini kamaytirish imkonini beradi.
Downloads
References
1. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC Guidelines on cardio-oncology. European Heart Journal. 2022;43(41):4229–4361.
2. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: IC-OS consensus statement. European Heart Journal. 2022;43(4):280–299.
3. Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in adult cancer survivors: ASCO guideline. Journal of Clinical Oncology. 2017;35(8):893–911.
4. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020;31(2):171–190.
5. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies. European Journal of Heart Failure. 2020;22(11):1945–1960.
6. Thavendiranathan P, Negishi T, Somerset E, et al. Strain-guided management of potentially cardiotoxic cancer therapy. Journal of the American College of Cardiology. 2021;77(4):392–401.
7. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in patients treated with immune checkpoint inhibitors. Journal of the American College of Cardiology. 2018;71(16):1755–1764.
8. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine. 2013;368(11):987–998.
9. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity. European Heart Journal. 2016;37(36):2768–2801.
